Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

BACKGROUND: Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There are, however, no data about the use of the XELIRI regimen in the neoadjuvant treatment. METHODS: Patients with unresectable liver-o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Skof, Erik, Rebersek, Martina, Hlebanja, Zvezdana, Ocvirk, Janja
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2678276/
https://ncbi.nlm.nih.gov/pubmed/19386096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-120
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares